Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03522298 · ClinicalTrials.gov registry record · Phase 2
Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
A Phase 2 study of Glioblastoma, Adult, sponsored by Kazia Therapeutics Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT03522298 is a Phase 2 study of Glioblastoma, Adult that has completed, run by Kazia Therapeutics Limited. The registered enrollment target is 30 participants. The trial reports 6 study locations across 6 states.
The verdict
NCT03522298, a Phase 2 study of Glioblastoma, Adult, has completed, sponsored by Kazia Therapeutics Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
This protocol has a 2-part design: This phase 2 study is an open-label, multicenter, dose-escalation and expansion study to assess the safety, tolerability, recommended phase 2 dose (RP2D), pharmacokinetics (PK) and clinical activity of paxalisib in patients with newly-diagnosed glioblastoma (GBM) with unmethylated MGMT promoter status as adjuvant therapy following surgical resection and initial chemoradiation with temozolomide (TMZ).
Conditions Studied
Interventions
- DRUG Paxalisib (GDC-0084)
Study Locations (6)
California
- University of California Los Angeles - Jonsson Comprehensive Cancer Center - Los Angeles
Colorado
- University of Colorado Cancer Center - Aurora
Massachusetts
- Dana Farber Cancer Institute - Boston
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
Oklahoma
- University of Oklahoma Health Sciences Center (Stephenson Cancer Center) - Oklahoma City
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-05-15 |
| Est. Completion | 2023-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03522298
The ClinicalTrials.gov registry entry for NCT03522298 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kazia Therapeutics Limited, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma, Adult appearing as the primary indexed condition, and to 1 intervention - of which Paxalisib (GDC-0084) is the first listed.
NCT03522298 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Colorado, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03522298 about?
NCT03522298 is a clinical study titled "Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma". This protocol has a 2-part design: This phase 2 study is an open-label, multicenter, dose-escalation and expansion study to assess the safety, tolerability, recommended phase 2 dose (RP2D), pharmacokinetics (PK) and clinical activity of paxalisib in patients with newly-diagnosed glioblastoma (GBM) ...
What is the current status of trial NCT03522298?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2018-05-15. Estimated completion is 2023-03-30.
What conditions does trial NCT03522298 study?
This clinical trial studies the following conditions: Glioblastoma, Adult.
What interventions are being tested in trial NCT03522298?
The interventions under investigation include: Paxalisib (GDC-0084) (DRUG).
Who is sponsoring clinical trial NCT03522298?
This trial is sponsored by Kazia Therapeutics Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03522298 being conducted?
This trial has 6 study locations across California, Colorado, Massachusetts, New Jersey, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.